Online citations, reference lists, and bibliographies.
← Back to Search

Statement On Malignant Mesothelioma In The UK

M. Robinson, J. Wiggins
Published 2002 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
We would like to provide the following additional material to Appendix 3 “Sources of information and help available for patients and carers” which appeared on 263–4 of the BTS statement on malignant mesothelioma in the UK published recently in Thorax . …
This paper references



This paper is referenced by
10.1136/thx.2010.151043.44
P193 The value of a regional mesothelioma multidisciplinary team meeting—an audit
A. Jeyabalan (2010)
10.1136/bmjopen-2015-010589
Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention
N. Bayman (2016)
10.1002/9781118990957.CH18
Mesothelioma: Screening in the modern age
Joanna Sesti (2018)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.1093/BMB/LDH040
Pleural effusion: a structured approach to care.
N. Rahman (2004)
10.1111/j.1365-2303.2010.00840.x
Should cytology be an acceptable means of diagnosing malignant mesothelioma?
M. Sheaff (2011)
10.1111/j.1445-5994.2010.02223.x
Malignant mesothelioma
S. Kao (2010)
10.1038/bjc.2017.20
Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma
Sanjeevan Muruganandan (2017)
10.1097/PAT.0b013e3283445e67
Molecular biomarkers in malignant mesothelioma: state of the art
S. Kao (2011)
10.1016/J.HOC.2005.09.007
Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein.
J. Creaney (2005)
10.1016/S1470-2045(16)30095-X
Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial
A. Clive (2016)
10.1136/bcr-2012-007491
Diagnostic delay in malignant pleural mesothelioma due to physicians fixation on history with non-exposure to asbestos
P. Madsen (2013)
10.1111/ans.12226
A case of peritoneal mesothelioma masquerading as a urachal mass
K. Huynh (2014)
10.1097/COC.0b013e3181d31f02
Expert Opinions of the First Italian Consensus Conference on the Management of Malignant Pleural Mesothelioma
C. Pinto (2011)
10.1183/09031936.00084611
Respiratory illness in asbestos contaminated sites: the role of environmental exposure
P. Comba (2011)
10.1016/j.ctro.2017.11.004
SYSTEMS-2: A randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma
M. Ashton (2018)
10.5694/j.1326-5377.2009.tb02321.x
Early detection of malignant pleural mesothelioma through measurement of soluble mesothelin‐related protein and positron emission tomography
E. O'Lone (2009)
10.1111/ajco.12306
Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: An evidence‐based benchmark for cancer care
Steven Chuan‐Hao Kao (2015)
10.1136/jclinpath-2012-201303
Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers
D. Henderson (2013)
10.1097/MCP.0b013e3282fcea50
Prophylactic radiotherapy for pleural puncture sites in mesothelioma: the controversy continues
H. E. Davies (2008)
10.1016/J.ARBR.2015.02.009
Diagnosis and Treatment of Malignant Pleural Mesothelioma
Francisco Rodríguez Panadero (2015)
INVITED REVIEW SERIES: COMPLICATIONS IN LUNG PROCEDURES
P. Lee (2009)
10.1186/s12904-017-0255-3
Exploring the characteristics of patients with mesothelioma who chose active symptom control over chemotherapy as first-line treatment: a prospective, observational, single centre study
Anna C. Bibby (2017)
10.1002/14651858.CD005574.PUB2
Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.
J. Green (2007)
10.1201/B13288-28
Pharmacological management in chronic respiratory diseases
Rachel Brown (2005)
10.1111/j.1445-5994.2012.02925.x
Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia
S. C.-H. Kao (2013)
10.1016/j.lungcan.2009.06.014
Prophylactic radiotherapy to intervention sites in mesothelioma: a systematic review and survey of UK practice.
C. Lee (2009)
10.1097/BRS.0b013e3181ae8294
Malignant Pleural Mesothelioma Presenting as Low Back Pain: Diagnosed by Bone Scan Coordinating With F-18 FDG PET/CT
Y. Huang (2009)
10.1136/bmjopen-2014-006673
Protocol for the surgical and large bore procedures in malignant pleural mesothelioma and radiotherapy trial (SMART Trial): an RCT evaluating whether prophylactic radiotherapy reduces the incidence of procedure tract metastases
A. Clive (2015)
10.1053/j.semtcvs.2009.06.007
Current status of screening for malignant pleural mesothelioma.
H. Pass (2009)
10.1016/b978-0-12-394384-2.00006-1
Asbestos-Related Disease
J. R. Portal (2012)
10.1183/09031936.00040911
A breath test for malignant mesothelioma using an electronic nose
Elaine. Chapman (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar